Skip to content

13F-HR filed by Fairmount Funds Management LLC

Fairmount Funds Management LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 20:45:21 UTC, with 12 holding rows worth $1,594,519,847.

Accession
0001104659-26-128188
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 12 entries on the cover page, a total value of $1,594,519,847 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,594,519,847 with VALUE read as dollars as filed, 13F file number 028-19908. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ORUKA THERAPEUTICS INC COM687604108Stock3,705,262$308,611,272dollars as filed
KORSANA BIOSCIENCES INC23255M303COMMON STOCK9,103,729$291,319,328dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM2,537,191$223,399,668dollars as filed
DAMORA THERAPEUTICS INCG2646Y104COMM STK8,713,000$185,412,640dollars as filed
COGENT BIOSCIENCES INC19240Q201COM5,503,418$176,219,444dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM5,090,928$104,822,208dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock1,855,644$85,062,721dollars as filed
JADE BIOSCIENCES INC008064206COM NEW4,553,494$63,976,591dollars as filed
ZENAS BIOPHARMA INC COM98937L105Stock2,371,358$63,955,525dollars as filed
CRESCENT BIOPHARMA INCG2545C104COMMON STOCK3,601,316$52,543,200dollars as filed
FAETH THERAPEUTICS INC81728A207COM NEW722,020$21,472,875dollars as filed
INHIBIKASE THERAPEUTICS INC45719W205COMMON STOCK8,625,000$17,724,375dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001104659-26-128188this filing2026-11-16